IMMUNOREACTIVITY FOR P53 PROTEIN IN MALIGNANT MESOTHELIOMA AND NONNEOPLASTIC MESOTHELIUM

被引:57
|
作者
RAMAEL, M
LEMMENS, G
EERDEKENS, C
BUYSSE, C
DEBLIER, I
JACOBS, W
VANMARCK, E
机构
[1] Department of Pathology, University Hospital Antwerp, University of Antwerp (U.I. A.), Edegem, 2650
来源
JOURNAL OF PATHOLOGY | 1992年 / 168卷 / 04期
关键词
MESOTHELIOMA; P53; PROTEIN; SUPPRESSOR ONCOGENE; IMMUNOHISTOCHEMISTRY; MESOTHELIUM;
D O I
10.1002/path.1711680406
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The presence of p53 protein in non-neoplastic pleural mesothelium (40 cases) and in human malignant mesothelioma (36 cases) was assessed immunohistochemically using the antibodies DO7, CM-1, and PAb240. In a quarter of the malignant mesotheliomas, there was nuclear immunoreactivity for p53 protein with both the DO7 and CM-I antibodies. There were no statistically significant differences between the various mesothelioma subtypes (P>0.05). No immunoreactivity was found with the PAb240 antibody, suggesting absence of mutant-type p53 protein. Non-neoplastic mesothelium was not immunoreactive with any of the antibodies. We conclude that there is immunoreactivity for p53 protein in some mesotheliomas. p53 protein immunoreactivity could be used to discriminate between neoplastic and reactive mesothelium.
引用
收藏
页码:371 / 375
页数:5
相关论文
共 50 条
  • [31] Pharmacological Targeting of p53 Effectively Induces Apoptosis in Malignant Mesothelioma Cell Lines
    Di Marzo, D.
    Forte, I. M.
    Indovina, P.
    Di Gennaro, E.
    Giorgi, F.
    Rizzo, V.
    Mattioli, E.
    Budillon, A.
    Giordano, A.
    Pentimalli, F.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S255 - S255
  • [32] The MDM2/p53 Axis is a Therapeutic Vulnerability in Malignant Pleural Mesothelioma
    Heasley, L.
    Hinz, T.
    Pacheco, J.
    Tirunagaru, V.
    Doebele, R.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S955 - S955
  • [33] P53 PROTEIN IN BENIGN AND MALIGNANT SWEAT GLAND TUMORS
    AKOSA, AB
    AMERICAN JOURNAL OF DERMATOPATHOLOGY, 1995, 17 (04) : 425 - 426
  • [34] P53 PROTEIN IN BENIGN AND MALIGNANT SWEAT GLAND TUMORS
    WIENECKE, R
    ECKERT, F
    KAUDEWITZ, P
    DEVIRAGH, PA
    HEIDL, G
    VOLKENANDT, M
    AMERICAN JOURNAL OF DERMATOPATHOLOGY, 1994, 16 (02) : 126 - 129
  • [35] p53 protein expression in benign and malignant breast lesions
    Ioakim-Liossi, A
    Markopoulos, C
    Karakitsos, P
    Safioleas, M
    Gogas, T
    Vaiopoulos, G
    ACTA CYTOLOGICA, 1998, 42 (04) : 918 - 922
  • [36] Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells
    Rao, Mahadev
    Atay, Scott M.
    Shukla, Vivek
    Hong, Young
    Upham, Trevor
    Ripley, R. Taylor
    Hong, Julie A.
    Zhang, Mary
    Reardon, Emily
    Fetsch, Patricia
    Miettinen, Markku
    Li, Xinmin
    Peer, Cody J.
    Sissung, Tristan
    Figg, William D.
    De Rienzo, Assunta
    Bueno, Raphael
    Schrump, David S.
    CLINICAL CANCER RESEARCH, 2016, 22 (05) : 1197 - 1210
  • [37] EXPRESSION OF THE P53 PROTEIN IN MALIGNANT MELANOMAS AS A PROGNOSTIC INDICATOR
    YAMAMOTO, M
    TAKAHASHI, H
    SAITOH, K
    HORIKOSHI, T
    TAKAHASHI, M
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 1995, 287 (02) : 146 - 151
  • [38] OVEREXPRESSION OF P53 PROTEIN IN BARRETTS SYNDROME WITH MALIGNANT TRANSFORMATION
    FLEJOU, JF
    POTET, F
    MUZEAU, F
    LEPELLETIER, F
    FEKETE, F
    HENIN, D
    JOURNAL OF CLINICAL PATHOLOGY, 1993, 46 (04) : 330 - 333
  • [39] ABNORMAL P53 IMMUNOREACTIVITY IN COLORECTAL CARCINOMAS
    VIALE, G
    BOSARI, S
    LEE, AKC
    COGGI, G
    LABORATORY INVESTIGATION, 1993, 68 (01) : A52 - A52
  • [40] Lack of p53 protein immunoreactivity in bilateral diffuse uveal melanocytic proliferation
    Margo, CE
    Lowery, RL
    Kerschmann, RL
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 1997, 17 (05): : 434 - 436